Short Interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Drops By 29.3%

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 8,200,000 shares, a decline of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily volume of 705,500 shares, the short-interest ratio is currently 11.6 days.

Analyst Upgrades and Downgrades

ATOS has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a report on Thursday, December 12th. Ascendiant Capital Markets increased their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th.

Atossa Therapeutics Stock Down 7.4 %

ATOS traded down $0.08 on Friday, hitting $0.98. 995,209 shares of the company traded hands, compared to its average volume of 1,061,169. Atossa Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.31. The company has a 50 day moving average of $1.27 and a 200-day moving average of $1.31. The stock has a market capitalization of $123.42 million, a PE ratio of -4.46 and a beta of 1.21.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics during the second quarter worth $29,000. Intech Investment Management LLC purchased a new position in Atossa Therapeutics during the 3rd quarter worth $29,000. SG Americas Securities LLC lifted its stake in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after acquiring an additional 30,037 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of Atossa Therapeutics in the third quarter valued at about $75,000. Finally, Rhumbline Advisers purchased a new stake in shares of Atossa Therapeutics in the second quarter valued at about $161,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.